SAN CARLOS, Calif., May 30 Nektar Therapeutics(Nasdaq: NKTR) will host a meeting and Webcast on Monday, June 2, 2008 at6:30 PM Central Time to discuss the company's lead oncology program, NKTR-102(PEG-irinotecan). The Webcast will include a presentation by featured speakerDr. Daniel D. Von Hoff, M.D., F.A.C.P, the lead investigator for the NKTR-102Phase 1 trial. Dr. Von Hoff is Physician-in-Chief and Senior Investigator atthe Translational Genomics Research Institute (TGen), Chief Scientific Officerfor the Scottsdale Clinical Research Institute at Scottsdale Healthcare, andChief Scientific Officer of US Oncology.
A live audio-only Webcast of this presentation can be accessed beginningat 6:30 PM Central Time on June 2, 2008 through a link posted on the Nektarwebsite: http://www.nektar.com/wt/page/asco. A replay will also be accessiblethrough the same link through June 15, 2008.
To attend this event in person, please RSVP no later than Sunday, June 1,2008 to Vanessa Rivas: firstname.lastname@example.org.
Nektar Therapeutics is a biopharmaceutical company that develops andenables differentiated therapeutics with its industry-leading PEGylation andpulmonary drug development platforms. Nektar PEGylation technology hasenabled eight approved products for partners, which include leadingpharmaceutical and biotechnology companies. Nektar also develops its ownproducts by applying its PEGylation and pulmonary technology platforms toexisting medicines with the objective to enhance performance, such asimproving efficacy, safety and compliance.
Contact: Jennifer Ruddock, +1-650-283-6253, email@example.comTime: 6:00 - 6:30 PM (Central Time) -- Registration 6:30 PM (Central Time) -- Webcast presentation Location: Fulton's on the River Riverfront Room and Veranda 315 N. LaSalle Street Chicago, IL 60610
SOURCE Nektar Therapeutics